Lacri-Lube | Patient Info | Allergan Ltd

Home
Medicines
Lacri-Lube

« Back to Medicines list

Name:
Lacri-Lube
Company:
Allergan Ltd
Active Ingredients:
No Active Ingredients
Legal Category:
Supply through pharmacy only

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 26/09/18

(Click to Download)

XPIL

PACKAGE LEAFLET: INFORMATION FOR THE USER

1. What LACRI-LUBE is and what it is used for

2. Before You Use LACRI-LUBE

3. How to use LACRI-LUBE

4. Possible side effects

5. How to store LACRI-LUBE

6. FURTHER INFORMATION

Summary of Product Characteristics last updated on medicines.ie: 18/12/2014

Print ViewKeyword Search SPC

1. NAME OF THE MEDICINAL PRODUCT

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

3. PHARMACEUTICAL FORM

4. CLINICAL PARTICULARS

5. PHARMACOLOGICAL PROPERTIES

6. PHARMACEUTICAL PARTICULARS

7. MARKETING AUTHORISATION HOLDER

8. MARKETING AUTHORISATION NUMBER(S)

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

10. DATE OF REVISION OF THE TEXT

Company Products

Medicine Name	Active Ingredients
Medicine Name Acular	Active Ingredients Ketorolac Trometamol
Medicine Name Alphagan	Active Ingredients brimonidine tartrate
Medicine Name Betagan Unit Dose	Active Ingredients Levobunolol hydrochloride
Medicine Name BOTOX 100 Units	Active Ingredients Botulinum Toxin Type A
Medicine Name BOTOX 200 Units	Active Ingredients Botulinum Toxin Type A
Medicine Name BOTOX 50 Units	Active Ingredients Botulinum Toxin Type A
Medicine Name Celluvisc 0.5%	Active Ingredients Carmellose sodium
Medicine Name Celluvisc 1.0% w/v Eye drops, solution	Active Ingredients Carmellose sodium
Medicine Name Combigan	Active Ingredients brimonidine tartrate, Timolol Maleate
Medicine Name Exocin	Active Ingredients Ofloxacin
Medicine Name FML	Active Ingredients Fluorometholone
Medicine Name Ganfort	Active Ingredients Bimatoprost, Timolol Maleate
Medicine Name Ganfort SD	Active Ingredients Bimatoprost, Timolol Maleate
Medicine Name Lacri-Lube	Active Ingredients No Active Ingredients
Medicine Name Liquifilm Tears	Active Ingredients Polyvinyl Alcohol
Medicine Name Lumigan 0.1mg/ml	Active Ingredients Bimatoprost
Medicine Name Ozurdex	Active Ingredients Dexamethasone
Medicine Name Pred Forte	Active Ingredients Prednisolone Acetate
Medicine Name Pred Mild	Active Ingredients Prednisolone Acetate
Medicine Name Refresh Ophthalmic	Active Ingredients Polyvinyl Alcohol, Povidone
Medicine Name Relestat 0.5 mg/ml, eye drops, solution	Active Ingredients Epinastine Hydrochloride
Medicine Name Vistabel	Active Ingredients Botulinum Toxin Type A

Items Per Page :

1 - 0 of 22 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 26 September 2018 PIL

Reasons for updating

Change to section 5 - how to store or dispose

Updated on 18 December 2014 SPC

Reasons for updating

New SPC for new product

Legal category: Supply through pharmacy only

Updated on 18 December 2014 SPC

Reasons for updating

Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

name change from IMB to HPRA

Updated on 17 December 2014 PIL

Reasons for updating

New PIL for new product

Updated on 17 December 2014 PIL

Reasons for updating

Change to side-effects

Updated on 22 May 2014 SPC

Reasons for updating

Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

The following wording have been added to the sec. 4.8 of the SPC:

(…)

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:

Earlsfort Terrace

IRL - Dublin 2

Tel: +353 1 6764971

Fax: +353 1 6762517

Website: www.imb.ie

e-mail: imbpharmacovigilance@imb.ie

Updated on 9 May 2014 PIL

Reasons for updating

Addition of information on reporting a side effect.

Updated on 6 September 2012 PIL

Reasons for updating

Change to side-effects
Correction of spelling/typing errors

Updated on 3 July 2012 SPC

Reasons for updating

Change to section 4.4 - Special warnings and precautions for use
Change to section 4.8 - Undesirable effects
Change to improve clarity and readability

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

General update of SmPC in line with QRD Templates
Updated wording of 4.4 & 4.8 to harmonise across EU

Updated on 16 August 2010 PIL

Reasons for updating

Correction of spelling/typing errors

Updated on 13 February 2009 PIL

Reasons for updating

New PIL for medicines.ie

Updated on 13 February 2009 SPC

Reasons for updating

Correction of spelling/typing errors

Legal category: Supply through pharmacy only

Updated on 9 March 2007 SPC

Reasons for updating

Change to section 6.3 - Shelf life
Change to section 6.5 - Nature and contents of container

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Added the following to 6.3 Shelf life - Opened: 1 month (28days)

6.5 Nature of contents of container - added "or HDPE cap"

An aluminium tube with an epoxy – phenolic resin or melamine-epoxy resin internal coating with an LDPE or HDPE cap containing 3.5g or 5g of sterile ophthalmic ointment.

Updated on 1 September 2006 SPC

Reasons for updating

Change to section 6.1 - List of excipients
Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 6.1 - Mineral Oil replaced with Liquid Paraffin and Lanolin alcohols replaced with Wool Alcohols.

Section 10 - date of revison updated to 19th September 2005

Updated on 15 August 2005 SPC

Reasons for updating

Change to section 1 - Name of medicinal product
Change to section 2 - Qualitative and quantitative composition
Change to section 3 - Pharmaceutical form
Change to section 4.4 - Special warnings and precautions for use
Change to section 4.6 - Pregnancy and lactation
Change to section 4.8 - Undesirable effects
Change to section 4.9 - Overdose
Change to section 5.1 - Pharmacodynamic properties
Change to section 6.5 - Nature and contents of container
Change to section 7 - Marketing authorisation holder
Change to section 9 - Date of renewal of authorisation
Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Updated on 27 June 2003 SPC

Reasons for updating

New SPC for medicines.ie

Legal category: Supply through pharmacy only